Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study

Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule ther

By: globenewswire_fr